Skip to content

Study · Animal study (in vivo) · rabbit · 1980

1 result

Vasoactive intestinal polypeptide (VIP) inhibits prostaglandin-F2 alpha-induced activity of the rabbit myometrium.

Ottesen B, Wagner G, Fahrenkrug J

Prostaglandins1 Mar 1980Cited by 20 (Europe PMC)

PMID7384549 (opens in a new tab)DOI10.1016/0090-6980(80)90076-3 (opens in a new tab)PepBankPUB-07384549
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rabbit myometrial autografts, VIP inhibited prostaglandin-F2 alpha-induced myometrial activity in a dose-dependent manner.

    In plain wordsIn rabbits, VIP reduced uterine muscle activity caused by prostaglandin-F2 alpha, and higher doses reduced it more.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreaseProstaglandin-F2 alpha-induced myometrial activity
    Study

    rabbitn = 7

    myometrial autografts in ear-chambers
    Comparator
    Prostaglandin-F2 alpha-induced activity without VIP
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Vasoactive intestinal polypeptide (VIP) dose-dependently inhibited myometrial activity induced by prostaglandin-F2 alpha.
    2 context sentences
    Summary · context
    Seven female rabbits ahd myometrial autografts transplanted into ear-chambers.
    Summary · context
    The electrical activity of the graft was recorded and mechanical activity observed.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.